UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas

P Pallante1, MT Berlingieri1, G Troncone2, M Kruhoffer3, TF Orntoft3, G Viglietto1, A Caleo2, I Migliaccio2, M Decaussin-Petrucci1, M Santoro1, L Palombini2 and A Fusco4,5

1Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli ‘Federico II’, via pansini, 5, 80131 Naples, Italy; 2Dipartimento di Anatomia Patologica e Citopatologia, Facoltà di Medicina e Chirurgia di Napoli, Università di Napoli Federico II, via pansini, 5, 80131 Naples, Italy; 3Department of Clinical Biochemistry, Aarhus University Hospital, Skejby DK 8200 Aarhus N, Denmark; 4Service d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Bérine, France; 5NOGEC (Naples Oncogenomic Center)-CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 80131 Naples, Italy

The hybridisation of an Affymetrix HG_U95Av2 oligonucleotide array with RNAs extracted from six human thyroid carcinoma cell lines and a normal human thyroid primary culture led us to the identification of the UbcH10 gene that was upregulated by 150-fold in all of the carcinoma cell lines in comparison to the primary culture cells of human normal thyroid origin. Immunohistochemical studies performed on paraffin-embedded tissue sections showed abundant UbcH10 levels in thyroid anaplastic carcinoma samples, whereas no detectable UbcH10 expression was observed in normal thyroid tissues, in adenomas and goiters. Papillary and follicular carcinomas were only weakly positive. These results were further confirmed by RT–PCR and Western blot analyses. The block of UbcH10 protein synthesis induced by RNA interference significantly reduced the growth rate of thyroid carcinoma cell lines. Taken together, these results would indicate that UbcH10 overexpression is involved in thyroid cell proliferation, and may represent a marker of thyroid anaplastic carcinomas.

Keywords: UbcH10; thyroid; carcinomas; immunohistochemistry

Tumours are the result of the accumulation of different modifications in critical genes involved in the control of cell proliferation. In a large number of carcinomas with worst prognosis, lesions are not diagnosed until the disease is at an advanced stage. Although various therapeutic approaches are followed in clinical practice, most of them are not life saving. Hence, the discovery of ways to diagnose cancer at an early stage and to establish more effective therapies is a critical and urgent issue. To achieve this goal, identification and characterisation of key molecules that participate in carcinogenesis are essential steps. Thyroid neoplasms represent a good model for studying the events involved in epithelial cell multistep carcinogenesis, because they comprise a broad spectrum of lesions with different degrees of malignancy from benign adenomas, which are not invasive and very well differentiated, to the undifferentiated anaplastic thyroid carcinomas, which are very aggressive and always fatal; papillary and follicular carcinomas, the most common forms of thyroid cancer, represent intermediate forms of neoplasia being differentiated and having a good prognosis (Hedinger et al, 1989; Wynford-Thomas, 1997).

The involvement of several oncogenes has been demonstrated in papillary thyroid carcinomas. Activation of the RET/PTC oncogene, caused by rearrangements of the RET protooncogene, is detectable in about 30% of the cases (Grieco et al, 1990; Tallini et al, 1998). Mutations of the B-raf gene have been demonstrated in almost 40% of papillary carcinomas (Fukushima et al, 2003). TRK gene rearrangements (Pierotti et al, 1995) and MET gene overexpression are often found in papillary carcinomas (Di Renzo et al, 1992). RAS gene mutations (Suarez et al, 1990) and PAX8-PPAR-γ2 rearrangements (Kroll et al, 2000) are frequently detected in tumours of the follicular type. Impairment of the p53 tumour suppressor gene function represents a typical feature of the anaplastic carcinomas (Ito et al, 1992; Dobashi et al, 1993; Donghi et al, 1993; Fagin et al, 1993; Matias-Guiu et al, 1994). Even though critical molecular mechanisms of thyroid carcinogenesis have been clarified, other molecular steps of neoplastic progression need to be investigated.

Therefore, to identify the genes regulated in the process of thyroid carcinogenesis, we analysed a microarray with RNAs extracted from normal human thyroid primary cell culture (NTPC), and six human thyroid carcinoma cell lines of different histotype (one from a follicular carcinoma, three derived from papillary carcinomas and two from anaplastic carcinomas). Our attention was focused on the UbcH10 gene that was upregulated...
about 150-fold in all of the cell lines tested by the cDNA microarray. The UbcH10 gene belongs to the E2 gene family and codes for a protein of 19.6 kDa that is involved in the ubiquitin-dependent proteolysis. In this pathway, ubiquitin-conjugating enzyme (E2), together with ubiquitin ligase (E3), transfers ubiquitin to specific substrate proteins (Hershko and Ciechanover, 1998; Joazeiro and Weissman, 2000).

The expression level of UbcH10 was extremely low in the normal thyroid primary culture cells, but strong in all the cancerous cell lines. Immunohistochemical and RT–PCR analyses on a large panel of thyroid neoplasms of different histotypes revealed an increased UbcH10 expression in anaplastic thyroid carcinomas, whereas follicular and papillary carcinomas were just weakly positive. The block of UbcH10 protein synthesis by RNA interference inhibited the growth of two thyroid carcinoma cell lines.

**MATERIALS AND METHODS**

**Cell culture and transfections**

The human thyroid carcinoma cell lines used in this study are: TPC-1 (Tanaka et al., 1987), WRO (Estour et al., 1989), NPA and ARO (Pang et al., 1989), FRO (Fagin et al., 1993), NIM 1 (Zeki et al., 1993), B-CPAP (Fabien et al., 1994), FB-1 (Fiore et al., 1997), FB-2 (Basolo et al., 2002), Kat-4 and Kat-18 (Ain et al., 1997). They were grown in DMEM (Gibco Laboratories, Carlsbad, CA, USA) containing 10% fetal calf serum (Gibco Laboratories), glutamine (Gibco Laboratories) and ampicillin/streptomycin (Gibco Laboratories) in a 5% CO2 atmosphere. Normal human thyroid primary culture cells have been established and grown as already described (Cucito et al., 1994). PC Cl 3 cell line derived from Fischer rat thyroid (Fusco et al., 1987) was cultured in modified F12 medium supplemented with 5% calf serum (Gibco Laboratories) and six growth factors (thyrotropic hormone, hydrocortisone, insulin, transferrin, somatostatin and glycyl-histidyl-lysine; Sigma, St Louis, MO, USA). Thyroid cells were transfected using Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The transfected cells were selected in a medium containing genetin (G418) (Life Technologies, Italy). For each transfection, several G418-resistant clones and the mass cell population were isolated and expanded for further analysis.

**Human thyroid tissue samples**

Neoplastic human thyroid tissues and normal adjacent tissue or the controlateral normal thyroid lobe were obtained from surgical specimens and immediately frozen in liquid nitrogen. Thyroid tumours were collected at the Service d’Anatomato-Pathologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France. The tumour samples were stored frozen until RNA or protein extractions were performed.

**RNA isolation**

Total RNA was extracted from tissues and cell cultures using the RNAeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. The integrity of the RNA was assessed by denaturing agarose gel electrophoresis.

**Reverse transcriptase–PCR analysis**

In total, 5 μg of total RNA from each sample, digested with DNaseI (Invitrogen), were reverse transcribed using random hexanucleotides and MuLV reverse transcriptase (Applied Biosystems, Foster City, CA, USA). PCR was carried out on cDNA using the GeneAmp PCR System 9600 (Applied Biosystems). RNA PCR Core Kit (Applied Biosystems) was used to perform RT–PCR reactions.

For the UbcH10 gene, after a first denaturing step (94°C for 3 min), PCR amplification was performed for 25 cycles (94°C for 30 s, 57°C for 30 s, 72°C for 30 s). The sequences of forward and reverse primers, amplifying a fragment of 115 bp in the UbcH10 cDNA, were: forward 5’-GCCCGTAAAGGAGCTGAG-3’ and reverse 5’-GGAAAGGCGAATACTCCCT-3’. The human β-actin gene primers, amplifying a 109 bp cDNA fragment, were used as control; amplification was performed for 25 cycles (94°C for 30 s, 55°C for 30 s, 72°C for 30 s). β-Actin-forward, 5’-TGTTGCCGTGACATTAGGAG-3’; β-actin-reverse, 5’-GTCAGGCGACTGCTAGCTCT-3’.

To ensure that RNA samples were not contaminated with DNA, negative controls were obtained by performing the PCR on samples that were not reverse-transcribed, but otherwise identically processed. The PCR products were separated on a 2% agarose gel, stained with ethidium bromide and scanned using a Typhoon 9200 scanner. Quantitative PCR was performed in triplicate using iCycler (Bio-Rad, Hercules, CA, USA) with SYBR<sup>®</sup> Green PCR Master Mix (Applied Biosystems) as follows: 95°C 10 min and 40 cycles (95°C 15 s and 60°C 1 min). Fold mRNA overexpression was calculated according to the formula 2:<sup>(Rt-Rn)/C0</sup> where Rt is the threshold cycle number for the reference gene in the tumour, Et for the experimental gene in the normal sample and En for the experimental gene in the normal sample.

**Protein extraction, Western blotting and antibodies**

Cells were washed once in cold PBS and lysed in a lysis buffer containing 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton-X-100, 1 mM phenylmethylsulphonyl fluoride, 1 μg aprotinin, 0.5 mM sodium orthovanadate, 20 mM sodium pyrophosphate. The lysates were clarified by centrifugation at 14000 r.p.m. × 10 min. Protein concentrations were estimated by a Bio-Rad assay (Bio-Rad), and boiled in Laemmli buffer (Tris-HCl pH 6.8, 0.125 M, SDS 4%, glycerol 20%, 2-mercaptoethanol 10%, bromophenol blue 0.002%) for 5 min before electrophoresis. Proteins were subjected to SDS–PAGE (15% polyacrylamide) under reducing condition. After electrophoresis, proteins were transferred to nitrocellulose membranes (Immobilon-P Millipore Corp., Bedford, MA, USA); complete transfer was assessed using prestained protein standards (Bio-Rad). Cells were washed once in cold PBS and lysed in a lysis buffer (Tris-HCl pH 6.8, 0.125 M, SDS 4%, glycerol 20%, 2-mercaptoethanol 10%, bromophenol blue 0.002%) for 5 min before electrophoresis. Proteins were subjected to SDS–PAGE (15% polyacrylamide) under reducing condition. After electrophoresis, proteins were transferred to nitrocellulose membranes (Immobilon-P Millipore Corp., Bedford, MA, USA); complete transfer was assessed using prestained protein standards (Bio-Rad). After blocking with TBS-BSA (25 mM Tris, pH 7.4, 200 mM NaCl, 5% bovine serum albumin), the membrane was incubated with the primary antibody against UbcH10 (Boston Biochem Inc., Cambridge, MA, USA) for 60 min (at room temperature). Primary antibody against c-Fos protein (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used to confirm the specificity of siRNAs against UbcH10 protein. To ascertain that equal amounts of protein were loaded, the Western blots were incubated with antibodies against the γ-tubulin protein (Sigma). Membranes were then incubated with the horseradish peroxidase-conjugated secondary antibody (1:3000) for 60 min (at room temperature) and the reaction was detected with a Western blotting detection system (ECL; Amersham Biosciences, UK).

**Immunohistochemistry: tissue samples**

UbcH10 protein cellular distribution was assessed by immunohistochemical analysis and compared to that of the standard cell proliferation marker Ki-67/MIB1. A series of surgical specimens from patients with thyroid diseases comprised of Hashimoto’s thyroiditis-HT (six cases), nodular goiter (12 cases), follicular carcinoma (13 cases), papillary carcinoma (33 cases), poorly differentiated carcinoma (five cases) and anaplastic carcinoma (15 cases) was chosen to represent a wide range of thyroid pathology. As control, 10 areas of normal thyroid parenchyma were selected from the lobe controlateral to the tumour in surgical specimens of papillary carcinoma.
Immunostaining: technique, evaluation and statistical analysis

Xylene dewaxed and alcohol-rehydrated paraffin sections were placed in Coplin jars filled with a 0.01 M tri-sodium citrate solution, and heated for 3 min in a conventional pressure cooker (Troncone et al., 2003). After heating, slides were thoroughly rinsed in cool running water for 5 min. They were then washed in Tris-Buffered Saline (TBS) pH 7.4 before incubating overnight with the specific antibody, diluted as follows: rabbit polyclonal UbcH10 (Boston Biochem) 1:1000; rabbit MIB-1 (Novocastra, Newcastle upon Tyne, UK) 1:50. After incubation with the primary antibody, tissue sections were stained with biotinylated anti-rabbit or anti-mouse immunoglobulins, followed by peroxidase-labelled streptavidine (Dako, Carpinteria, CA, USA); the signal was developed by using diaminobenzidine (DAB) chromogen as substrate. Incubations both omitting the specific antibody, and including unrelated antibodies, were used as negative controls.

Individual cells were scored for expression of UbcH10 and Ki-67 in similar areas of adjacent sections by quantitative analysis performed with a computerised analyser system (Ibas 2000, Kontron, Zeiss), as already described (Troncone et al., 2003). In each case, the distribution of these proteins was evaluated in at least 500 epithelial follicular cells and expressed as a percentage of the total cell population. The statistical analysis was performed using SPSS Ver. 9.0.1 for Windows®. Data are expressed as median value and range. The nonparametric Mann–Whitney U-test was used to compare differences in labelling indexes for UbcH10 and Ki-67 in thyroid carcinomas. The Spearman rank order correlation was used to verify the association between UbcH10 and Ki-67. A P-value less than 0.05 was considered statistically significant.

RNA interference

For small interfering RNA (siRNA) experiments, the following double-strand RNA oligo specific for UbcH10 coding region was used: 5′-AACCTGCAAGAAACCTACTCA-3′ as previously described (Wagner et al., 2004). As negative control, we used a corresponding scrambled sequence as follows: 5′-AACTAACAC TAGCTCAAGACC-3′. All of the siRNA duplexes were purchased from Qiagen and were transfected using Oligofectamine (Invitrogen) according to the manufacturer’s recommendations. Small interfering RNAs were used at a final concentration of 100 nM and 12 × 10⁵ cells well⁻¹ were plated in a six-well format plates. Proteins were extracted 48 h after siRNA treatment and the levels of the UbcH10 protein were evaluated by Western blot.

Assay of the transformed state

Tumorigenicity of the cell lines was tested by injecting 2 × 10⁶ cells subcutaneously into athymic mice. Soft agar colony assay was performed as previously described (Macpherson and Montagnier, 1964).

RESULTS

Expression of UbcH10 gene in normal human thyroid cells and thyroid carcinoma cell lines

To search for candidate genes involved in the neoplastic transformation of thyroid gland, RNAs extracted from normal human thyroid primary cells and six human thyroid carcinoma cell lines of different origin (WRO cell line from a follicular carcinoma, TPC-1 and FB-2 cell lines, both deriving from papillary thyroid cancers, NPA cell line, which derives from a poorly differentiated papillary carcinoma, ARO and FRO cell lines originating from anaplastic carcinomas) were hybridised to U95Aa2 Affymetrix oligonucleotide arrays (data not shown). We

Concentrated our attention on the UbcH10 gene that was upregulated about 150-fold in all of the cell lines tested by the cDNA microarray. This result was confirmed by RT–PCR in a larger panel of thyroid carcinoma cell lines using as control normal thyroid primary culture (Figure 1A). Western blot analysis of UbcH10 expression, shown in Figure 1B, confirmed the RT–PCR data. In fact, the UbcH10 protein was abundantly expressed in all of the carcinoma cell lines, whereas it was barely detectable in normal thyroid cells.

Analysis of UbcH10 expression in normal and neoplastic thyroid tissues by immunohistochemistry, Western blot and RT–PCR

In order to evaluate whether the overexpression of UbcH10 is a feature of the thyroid tumours and not only of cultured thyroid carcinoma cell lines, we performed immunohistochemical analysis using a commercial antibody against UbcH10 protein. This methodology allows a rapid and sensitive screening of thyroid pathological tissues and is amenable to regular use as a routine diagnostic test. To find the best experimental conditions, ARO cell line and tumours, induced by injecting the ARO cell line into athymic mice, were used as positive controls (Cerutti et al., 1996). No staining was observed with normal human thyroid primary cell culture, whereas a positive staining was obtained with ARO cell line and ARO-induced tumours (data not shown). We found that normal thyroid, nodular goiter and Hashimoto’s thyroiditis (HT) were almost always completely negative for UbcH10 expression. Only occasionally, single UbcH10-labelled thyroid epithelial cells showing mitotic figures could be observed by meticulous scrutiny (Figure 2A). In HT, there was a sharp contrast between the negative epithelial oxyphilic cells and the positive lymphoid germinal centers (Figure 2B). While a weak staining is detectable in follicular adenomas (Figure 2C), higher levels of UbcH10 were recorded in papillary (median value 2.2% of positive cells; range 0.9–4.1%), follicular (median value 2.8% of positive cells; range 1–6.1%) and poorly differentiated (median value 10.4% of positive cells; range 8–14.9%) carcinomas, signal being always easily detectable in the nuclei of scattered neoplastic cells (Figure 2D, E and F). UbcH10 staining pattern was somewhat different in
anaplastic carcinomas, the percentage (median value 45.8% of positive cells; range 38.8–56.2%) of stained cells being large and the intensity of the neoplastic cells being strong (Figure 2G and H).

No staining was observed when the same anaplastic carcinoma samples were stained with antibodies preincubated with UbcH10 recombinant protein (Figure 2I) or in the absence of the primary antibodies (data not shown). Therefore, as a general rule, UbcH10 expression is negligible in non-neoplastic thyroid, noticeable in well-differentiated carcinomas and conspicuous in less-differentiated tumours (Figure 3A).

To determine the relationship between UbcH10 expression and tissue proliferation, we correlated its expression in carcinomas with the proliferation rate of thyrocytes, as measured by Ki-67 staining; this latter showed the same tissue distribution of UbcH10, which was evident when adjacent (mirror) sections were stained. By using the Spearman rank order correlation, we determined that the association between UbcH10 and Ki-67 expression in thyroid cancer was statistically significant. In fact, the value of the Spearman R was 0.4 (P < 0.001) (Figure 3B).

Western blot analysis, performed on 30 surgically removed thyroid tumours, confirmed the immunohistochemical data. A representative Western blot is shown in Figure 4A. A strong band of 19.6 kDa corresponding to the UbcH10 protein was detected in anaplastic thyroid carcinomas and a weak one in poorly differentiated carcinomas, but not in papillary carcinomas and normal thyroids. These data strongly indicate that the expression of UbcH10 is more abundant in thyroid carcinomas characterised by a highly malignant and aggressive phenotype. Equal amounts of total proteins were used for each sample as demonstrated by the same gel analysed with an antibody against γ-tubulin.

UbcH10 expression was also evaluated by RT–PCR analysis on a panel of matched tumour/normal tissues. This analysis confirmed the protein data. In fact, as shown in Figure 4B, an amplified band of 115 bp was clearly detected in the anaplastic and poorly differentiated carcinoma samples, but not in the papillary ones and in all the corresponding normal thyroid tissues. Finally, quantitative RT–PCR analysis confirmed a great increase of UbcH10 expression in thyroid anaplastic samples, whereas a light increase was observed in papillary carcinoma samples (Figure 4C).

UbcH10 expression in experimental models of thyroid carcinogenesis

Thyroid neoplasias developing in transgenic animal lines expressing TRK (Tg-TRK) (Russell et al, 2000), RET/PTC3 (Tg-RET/PTC3) (Powell et al, 1998) and large T SV40 (Tg-SV40) (Ledent et al, 1991) oncogenes under the transcriptional control of the thyroglobulin promoter have been analysed for UbcH10 expression by Western blot analysis. Transgenic mice carrying TRK and RET/PTC3 oncogenes develop thyroid papillary carcinomas (Powell et al, 1998; Russell et al, 2000); thyroid anaplastic carcinomas were, conversely, obtained in the Tg-SV40 mice.
Ledent et al., 1991). As shown in Figure 5, elevated UbcH10 protein levels were observed in the thyroid anaplastic carcinomas derived from large T SV40 transgenic mice. Conversely, UbcH10 protein was absent in normal mouse thyroid tissue and in the papillary carcinomas originating from TRK and RET/PTC3 mice.

Therefore, the analysis of the experimental models of thyroid carcinogenesis seems to confirm that the UbcH10 overexpression is essentially restricted to the undifferentiated histotype.

**Suppression of the UbcH10 synthesis inhibits thyroid carcinoma cell growth**

We asked whether UbcH10 overexpression had a role in the process of thyroid carcinogenesis by evaluating the growth rate of two thyroid carcinoma cell lines, in which UbcH10 protein was suppressed by RNA interference. The NPA and TPC-1 cell lines were treated with siRNA duplexes targeting to the UbcH10 mRNA. After transfection, we observed an efficient knockdown of the UbcH10 protein levels at 48 h after treatment (Figure 6A). The analysis of cell growth of these cell lines in the presence or absence of the UbcH10 siRNA duplexes revealed that the block of the UbcH10 protein synthesis significantly inhibits thyroid carcinoma...
expression of cell lysates were prepared and normalised for protein concentration. The evaluated by Western blot analysis. At 48 h after siRNA transfection, total UbcH10 protein expression by RNAi in NPA and TPC-1 cell lines inhibits the proliferation of thyroid carcinoma cells. (Figure 6)

The block of UbcH10 protein synthesis by RNA interference (Figure 6A) in inhibits the proliferation of thyroid carcinoma cells. (A) Inhibition of UbcH10 protein expression by RNAi in NPA and TPC-1 cell lines evaluated by Western blot analysis. At 48 h after siRNA transfection, total cell lysates were prepared and normalised for protein concentration. The expression of γ-tubulin was used to control equal protein loading (30 μg). In this figure, we also show the expression of a fast turning-over gene like c-Fos to confirm the specific effect of siRNAs against UbcH10. (B) Growth curves of NPA and TPC-1 cell lines after siUbcH10 treatment. NPA and TPC-1 cells were transfected with siUbcH10 duplexes (siUbcH10) and the relative number of viable cells was determined by MTT assay. Cells transfected with a scrambled duplex (siScrambled) and untransfected cells (Untransfected) were used as negative controls. Absorbance was read at 570 nm and the data are the mean of triplicates.

Table 1 Analysis of the neoplastic phenotype of the UbcH10-transfected rat thyroid cell lines

| Cell line     | Doubling time (h) | Colony-forming efficiency (%) | Tumour incidence |
|---------------|-------------------|-------------------------------|------------------|
| PC CL 3       | 24                | 0                             | 0/4              |
| PC UbcH10 CL1 | 24                | 0                             | 0/4              |
| PC UbcH10 CL2 | 23                | 0                             | 0/4              |
| PC MPSV       | 18                | 70                            | 4/4              |

*Colony-forming efficiency was calculated by the formula (number of colonies formed/number of plated cells) x 100. †Tumorigenicity was assayed by injecting 2 x 10⁶ cells into athymic mice (4–6 weeks old).

In our study, we have evaluated the expression of UbcH10 in human thyroid neoplasias and in mouse experimental tumours. No cell growth. In fact, as shown in Figure 6B, a significant reduction in cell growth rate was observed in NPA and TPC-1 cell lines treated with UbcH10 siRNA in comparison to the untreated cells or those treated with the control scrambled siRNA.

These results indicate a role of UbcH10 in neoplastic thyroid cell proliferation.

UbcH10 overexpression is not sufficient to transform rat thyroid cells

To further characterise the role of UbcH10 in thyroid carcinogenesis, we transfected normal rat thyroid cells with an expression vector carrying the UbcH10 gene under the transcriptional control of the cytomegalovirus promoter. The selected clones were shown to express high UbcH10 protein levels (data not shown). We evaluated the growth rate of the UbcH10-transfected PC Cl 3 cells and the same cells transfected with a backbone vector: no differences were observed. Equally, the neoplastic phenotype of the UbcH10-transfected PC Cl 3 cells was evaluated by a soft agar colony assay and by injection into athymic mice. As reported in Table 1, the PC Cl 3 cells transfected with the UbcH10 expression vector were not able to give rise to colonies in soft agar and induce tumours in athymic mice. As a positive control, we used the PC Cl 3 cells transformed with the Myeloproliferative sarcoma virus (PC MPSV); these cells have a very highly malignant phenotype (Fusco et al., 1987).

These results indicate that UbcH10 overexpression is not able to transform rat thyroid cells in vitro.

DISCUSSION

Thyroid neoplasms represent an excellent model for studying the process of cell transformation since they include a broad spectrum of histotypes showing different degree of malignancy (Hedinger et al., 1989; Wynford-Thomas, 1997). From the Affymetrix microarray analysis, we found the UbcH10 gene that appeared greatly increased in all of the thyroid carcinoma cell lines. UbcH10 was previously identified as a human homologue of the cyclin-selective E2 (E2-c), which is required for the destruction of mitotic cyclins by the ubiquitination pathway. The UbcH10 gene belongs to the E2 gene family and codes for a protein of 19.6 kDa that is involved in the ubiquitin-dependent proteolysis. In this system, three distinct enzymes cooperate to process target proteins for degradation. More precisely, the ubiquitin-conjugating enzyme (E2) transfers activated ubiquitin by ubiquitin-activating enzyme (E1) to a lysine residue of the target proteins in cooperation with the ubiquitin-ligase (E3). Polyubiquitinated proteins are then recognised by the 26S proteasome and rapidly degraded (Hershko and Ciechanover, 1998; Jääsaari and Weissman, 2000).

In our study, we have evaluated the expression of UbcH10 in human thyroid neoplasias and in mouse experimental tumours. No
significant UbcH10 expression was observed in normal thyroids, goiters and adenomas, whereas a great induction of UbcH10 expression was observed in anaplastic human thyroid carcinomas and in experimental undifferentiated thyroid tumours. Just a weak expression of UbcH10 was observed in follicular and papillary human thyroid carcinomas. Therefore, these data strongly indicate that UbcH10 overexpression could be associated with the thyroid tumour progression since there is a good correlation with the late stage of thyroid neoplastic transformation. The low UbcH10 levels detected in the differentiated thyroid malignancies would appear in contrast with the data showing an abundant UbcH10 expression in the cell lines deriving from differentiated carcinomas. We retain this discrepancy only apparent since thyroid carcinoma cell lines, even deriving from differentiated tumours, cannot be completely compared to surgically removed tumours. In fact, these cell lines harbour p53 mutations that are rare in thyroid differentiated neoplasias (Tanaka et al., 1987; Estour et al., 1989; Pang et al., 1989; Ito et al., 1992; Dobashi et al., 1993; Donghi et al., 1993; Fagin et al., 1993; Zeki et al., 1993; Fabien et al., 1994; Matias-Guiu et al., 1994; Ain et al., 1997; Fiore et al., 1997; Basolo et al., 2002) and they have a high proliferation rate. However, this consideration does not exclude the validity of the use of the thyroid carcinoma cell lines as experimental model to draw new information that, however, need to be subsequently validated on fresh tumours.

Our results also indicate a correlation between UbcH10 overexpression and the proliferation status since there is a good association with the proliferation marker Ki-67/MIB1.

An aim of our work was to evaluate the possible causal role of UbcH10 overexpression in thyroid carcinogenesis. Indeed, the block of protein synthesis significantly inhibited the growth of several thyroid carcinoma cell lines, suggesting an important role of UbcH10 in thyroid cell proliferation, and then in the progression step of thyroid carcinogenesis.

Therefore, even though the mechanisms by which UbcH10 overproduction contributes to the neoplastic phenotype remains unclear, we can assume that it leads to a deregulation of cell growth. These results are quite consistent with previous published data showing that UbcH10 was expressed at high levels in primary tumours derived from the lung, stomach, uterus, and bladder as compared with their corresponding normal tissues, suggesting that UbcH10 is involved in tumorigenesis or cancer progression (Okamoto et al., 2003; Wagner et al., 2004). It has also been shown that UbcH10 is upregulated in NIH3T3 cell line transformed by EWS/FLI1, but not in untransformed NIH3T3 cell clone expressing EWS/FLI1 (Arvand et al., 1998).

Moreover, it has been shown that UbcH10 is required for override metaphase, likely growing growth suppressor, and for destruction of mitotic cyclins, indicating a role of UbcH10 in cell cycle progression (Arvand et al., 1998).

However, overexpression of UbcH10 in normal rat thyroid cells did not affect cell growth neither induced a malignant phenotype, indicating that UbcH10 overexpression is not sufficient for malignant thyroid cell transformation. This result might appear in contrast with those showing that NIH3T3 stable transfectants overexpressing UbcH10 exhibited a malignant phenotype as compared with parental NIH3T3 cells (Okamoto et al., 2003). This discrepancy is, in our opinion, just apparent since we have to consider that NIH 3T3 cells are preneoplastic cells, whereas PC 12 cells are much more resistant to express the neoplastic phenotype, since even the expression of several oncoproteins (v-ras-Ki, v-ras-Ha, etc.) are not able to lead these cells to the fully malignant phenotype that is achieved only when there is a synergy of two different oncoproteins (Fusco et al., 1987). In conclusion, our data propose the UbcH10 overexpression as a feature of the anaplastic carcinoma histotype. The block of UbcH10 expression significantly reduced the growth of thyroid carcinoma cell lines indicating an involvement of UbcH10 in the increased proliferation of these carcinoma cell lines. Therefore, these results open the perspective of a therapy of the anaplastic thyroid carcinoma, one of the most aggressive tumours in mankind, based on the suppression of the UbcH10 synthesis and/or function.

ACKNOWLEDGEMENTS

This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC), Progetto Strategico Oncologia Consiglio Nazionale delle Ricerche, the Ministero dell’Università e della Ricerca Scientifica e Tecnologica (MIUR), and Piani di Potenziamento della Rete Scientifico e Tecnologica’ CLUSTER C-04, the Programma Italia-USA sulla Terapia dei Tumori coordinato by Professor Cesare Peschle, and ’Ministero della Salute’. This work was supported from NOGEC-Naples Oncogenomic Center. We thank the Associazione Partenopea per le Ricerche Oncologiche (APRO) for its support. We are grateful to Jean Ann Gilder (Scientific Communication) for editing the text.

REFERENCES

Ain KB, Taylor KD, Tofiq S, Venkataraman G (1997) Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82: 1857 – 1862

Arvand A, Bastians H, Welford SM, Thompson AD, Ruderman JV, Denny CT (1998) EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 17: 2039 – 2045

Basolo F, Giannini R, Toniole A, Casalone R, Nikiforova M, Pacini F, Elisei R, Miccoli P, Berti P, Favia P, Fiore L, Monaco C, Pierantoni GM, Fedele M, Nikiforov YE, Santoro M, Fusco A (2002) Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. Int J Cancer 97: 608 – 614

Cerutti J, Trappaso F, Battaglia C, Zhang L, Martelli ML, Visconti R, Berlingerio MT, Fagin JA, Santoro M, Fusco A (1996) Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. Clin Cancer Res 2: 119 – 126

Curcio F, Ambevi-Impiombo FS, Perrella G, Coon HG (1994) Long-term culture and functional characterization of follicular cells from adult normal human thyroids. Proc Nail Acad Sci USA 91: 9004 – 9008

Di Renzo MF, Olivero M, Ferro S, Prat M, Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R, Pierotti MA (1992) Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7: 2549 – 2553

Dobashi Y, Sakamoto A, Sugimura H, Menyei M, Mori M, Oyama T, Machinami R (1993) Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17: 375 – 381

Donghi R, Longoni A, Pilotti S, Michepi P, Della Porta G, Pierotti MA (1993) Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753 – 1760

El-Rifai W, Frierion Jr HF, Moskaluk CA, Harper JC, Petroni GR, Bissonnette AE, Jones DR, Knuutila S, Powell SM (2001) Genetic differences between adenocarcinomas arising in Barrett’s esophagus and gastric mucosa. Gastroenterology 121: 592 – 598

Estour B, Van Herle AJ, Juillard G, Totanes TL, Sparkes RS, Giuliano AE, Elisei R, Miccoli P, Berti P, Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C (1994) Genetic differences between adenocarcinomas arising in Barrett’s esophagus and gastric mucosa. Proc Natl Acad Sci USA 91: 167 – 174

Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP (1993) High prevalence of mutations of p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179 – 184

This work was supported from NOGEC-Naples Oncogenomic Center. We thank the Associazione Partenopea per le Ricerche Oncologiche (APRO) for its support. We are grateful to Jean Ann Gilder (Scientific Communication) for editing the text.

© 2005 Cancer Research UK
Fiore L, Pollina LE, Fontanini G, Casalone R, Berlingieri MT, Giannini R, Pacini F, Miccoli P, Toniolo A, Fusco A, Basolo F (1997) Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. J Clin Endocrinol Metab 82: 4094 – 4100

Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S (2003) BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22: 6455 – 6457

Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Greico M, Vecchio G (1987) One- and two-step transformation of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 7: 3365 – 3370

Greico M, Santoro M, Berlingieri MT, Mellilo RM, Donghi R, Bongarzone I, Pietroiti MA, Della Porta G, Fusco A, Vecchio G (1990) PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557 – 563

Hedinger C, Williams D, Sobin LH (1989) The WHO histological classification of thyroid tumours: a commentary on the second edition. Cancer 63: 908 – 911

Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67: 425 – 479

Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M (1992) Unique association of p53 mutations with undifferentiated but not differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369 – 1371

Iozzo AR, Weissman AM (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell 102: 549 – 552

Kroll TG, Sarraf P, Pecciariini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA (2000) PAX-8-PARgamma1 fusion oncogene in human thyroid carcinoma. Science 289: 1357 – 1360

Ledent C, Dumont J, Vassart G, Parmentier M (1991) Thyroid adenoscinomas secondary to tissue-specific expression of simian virus-40 large T-antigen in transgenic mice. Endocrinology 129: 1391 – 1401

Macpherson I, Montagnier I (1964) Agar suspension culture for the selective assay of cells transformed by polyoma virus. Virology 23: 291 – 294

Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J (1994) p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 47: 337 – 339

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A (2003) UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 63: 4167 – 4173

Pang XP, Hershman JM, Chung M, Pekary AE (1989) Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 125: 1783 – 1788

Pierotti MA, Borangiere I, Borrello MG, Mariani C, Miranda C, Sozzi G, Greco A (1995) Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J Endocrinol Invest 18: 130 – 133

Powell Jr DJ, Russel J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A, Rothstein JL (1998) The RET/PTC oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 58: 5523 – 5528

Russell JP, Powell DJ, Cunnane M, Greco A, Portella G, Santoro M, Fusco A, Rothstein JL (2000) The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 19: 5729 – 5735

Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R (1990) Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5: 565 – 570

Tallini G, Santoro M, Helie M, Carlonamago F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4: 287 – 294

Tanaka J, Ogura T, Sato H, Datano M (1987) Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology 161: 62 – 72

Troncone G, Iaccarino A,raleo A, Bifano D, Pettinato G, Palombini L, (2003) p27 Kip1 protein expression in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 88: 587 – 591

Wagner KW, Sapinose LM, El-Rifai W, Frierson Jr HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM (2004) Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23: 6621 – 6629

Wynford-Thomas D (1997) Origin and progression of thyroid carcinomas. J Endocrinol Metab 76: 127 – 133